These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 31409327)

  • 1. Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study.
    Barrett LE; Gardner HL; Barber LG; Sadowski A; London CA
    BMC Vet Res; 2019 Aug; 15(1):291. PubMed ID: 31409327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma.
    Bracha S; Walshaw R; Danton T; Holland S; Ruaux C; Obradovich J
    J Small Anim Pract; 2014 Jul; 55(7):369-74. PubMed ID: 24803081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.
    Little PR; King VL; Davis KR; Cosgrove SB; Stegemann MR
    Vet Dermatol; 2015 Feb; 26(1):23-30, e7-8. PubMed ID: 25496303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety evaluation of combination carboplatin and toceranib phosphate (Palladia) in tumour-bearing dogs: A phase I dose finding study.
    Wouda RM; Hocker SE; Higginbotham ML
    Vet Comp Oncol; 2018 Mar; 16(1):E52-E60. PubMed ID: 28799187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canine intranasal tumours treated with alternating carboplatin and doxorubin in conjunction with oral piroxicam: 29 cases.
    Woodruff MJ; Heading KL; Bennett P
    Vet Comp Oncol; 2019 Mar; 17(1):42-48. PubMed ID: 30146732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog.
    Bailey D; Erb H; Williams L; Ruslander D; Hauck M
    J Vet Intern Med; 2003; 17(2):199-205. PubMed ID: 12683621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.
    Cosgrove SB; Cleaver DM; King VL; Gilmer AR; Daniels AE; Wren JA; Stegemann MR
    Vet Dermatol; 2015 Jun; 26(3):171-9, e35. PubMed ID: 25688708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of oclacitinib in the management of ischaemic dermatopathy in four dogs.
    Levy BJ; Linder KE; Olivry T
    Vet Dermatol; 2019 Jun; 30(3):201-e63. PubMed ID: 31006925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs.
    Schäfer L; Thom N
    Vet Dermatol; 2024 Aug; 35(4):408-417. PubMed ID: 38465482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
    Cosgrove SB; Wren JA; Cleaver DM; Walsh KF; Follis SI; King VI; Tena JK; Stegemann MR
    Vet Dermatol; 2013 Dec; 24(6):587-97, e141-2. PubMed ID: 24581322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of topical oclacitinib 0.1% and tacrolimus 0.01% in canine keratoconjunctivitis sicca.
    de Oliveira JK; Williams DL; Bollmann C; de Seabra NM; Bortolini M; Montiani-Ferreira F
    Vet Ophthalmol; 2019 Sep; 22(5):633-643. PubMed ID: 30724448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs.
    Marsella R; Ahrens K
    Vet Dermatol; 2018 Oct; 29(5):439-e146. PubMed ID: 29926994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.
    Cosgrove SB; Wren JA; Cleaver DM; Martin DD; Walsh KF; Harfst JA; Follis SL; King VL; Boucher JF; Stegemann MR
    Vet Dermatol; 2013 Oct; 24(5):479-e114. PubMed ID: 23829933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of taurolidine alone and in combination with doxorubicin or carboplatin in canine osteosarcoma in vitro.
    Marley K; Helfand SC; Edris WA; Mata JE; Gitelman AI; Medlock J; Séguin B
    BMC Vet Res; 2013 Jan; 9():15. PubMed ID: 23331343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma.
    Selmic LE; Burton JH; Thamm DH; Withrow SJ; Lana SE
    J Vet Intern Med; 2014; 28(2):554-63. PubMed ID: 24512451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks.
    Panteri A; Strehlau G; Helbig R; Prost C; Doucette K
    Vet Dermatol; 2016 Feb; 27(1):22-e7. PubMed ID: 26660461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
    Pellin MA; Wouda RM; Robinson K; Tsimbas K; Kurzman ID; Biller BJ; Vail DM
    Vet Comp Oncol; 2017 Sep; 15(3):919-931. PubMed ID: 27146577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carboplatin versus alternating carboplatin and doxorubicin for the adjuvant treatment of canine appendicular osteosarcoma: a randomized, phase III trial.
    Skorupski KA; Uhl JM; Szivek A; Allstadt Frazier SD; Rebhun RB; Rodriguez CO
    Vet Comp Oncol; 2016 Mar; 14(1):81-7. PubMed ID: 24118677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs.
    Allstadt Frazier S; McKemie DS; Guerrero TA; LaChapelle H; Skorupski KA; Kass PH; Rodriguez CO
    Vet Comp Oncol; 2014 Mar; 12(1):1-9. PubMed ID: 22364238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
    Simpson AC; Schissler JR; Rosychuk RAW; Moore AR
    Vet Dermatol; 2017 Oct; 28(5):485-e113. PubMed ID: 28513001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.